Advertise on podcast: Katy's 340B Compass: Compliance Made Clear

Audit readiness starts with everyday program control. In this episode, Katy Lees, Principal 340B Compliance Advisor at Virtue 340B, shares practical guidance on preparing data, organizing documentation, assigning ownership, protecting sensitive information, and answering audit questions with clarity. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

340B growth is real, but the story behind it is more complex than dollar totals alone suggest. In this episode, Katy Lees examines how rising drug acquisition costs, patient complexity, and changes in care delivery shape the conversation around 340B spending. She offers practical insight for leaders seeking clearer oversight and more balanced policy discussions. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

Strong 340B oversight starts with knowing where exposure exists and whether your methodology can be explained, documented, and validated. In this episode, Katy Lees, Principal 340B Compliance Advisor at Virtue 340B, discusses patient definition, offsite eligibility, duplicate discounts, Medicaid alignment, and recertification through a governance-focused lens. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

Katy Lees examines proposed cuts to 340B OPPS reimbursement and compares two emerging legislative frameworks: the SECURE 340B Act and the Integrity/Affordability draft. This episode helps leaders understand the oversight, financial, contract pharmacy, patient affordability, and operational considerations shaping today’s 340B policy environment. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

Manufacturer data-sharing discussions often assume that the requested information has already been sent to payers. Katy Lees explains why that is not always true, especially when 340B eligibility is determined after claim adjudication through accumulation, qualification, and replenishment processes. This episode offers practical insight for leaders evaluating risk, oversight, and operational realities. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

Communicating the value of your 340B program requires more than data—it requires clarity, alignment, and consistency. Katy Lees outlines how organizations can articulate program impact, strengthen stakeholderunderstanding, and translate social ROI into meaningful insight. A practical discussion for leaders focused on compliance, oversight, and operational visibility. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

The definition of a 340B “patient” is under legal scrutiny in AbbVie v. HHS, raising new questions about eligibility, audit risk, and oversight. Katy unpacks how outdated guidance, manufacturer challenges, and recent court rulings may reshape compliance expectations. This episode focuses on what leaders need to understand now to maintain clarity and defensibility. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

A federal court decision has vacated HRSA’s 2013 GPO policy, but what does that actually mean for your 340B program? Katy Lees unpacks the difference between inventory purchasing flexibility and ongoing compliance obligations, highlighting where risk remains. This episode focuses on practical implications for pharmacy operations, replenishment models, and audit exposure. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

A court ruling is redefining how 340B eligibility isinterpreted—separating it from OPAIS registration. Katy Lees explains what this means for offsite locations, how to establish a defensible eligibility date, and why documentation and alignment across teams now matter more than ever.This episode focuses on practical, governance-driven decision-making in a changing environment. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

What does transparency really mean in the 340B program? In this episode, Katy Lees examines the growing push for more visibility into 340B operations—and the practical challenges behind it. She explores the limitations of contractual data, the complexity of medical claims, emerging state reporting requirements, and recent legal developments shaping the transparency debate. Katy also discusses why standardized, neutral reporting frameworks may be necessary to improve clarity without creating misleading narratives. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

What did the Winter Coalition meeting signal about the future of 340B? Katy Lees shares key insights on Medicare Fair Price implementation, 340B identification in reporting, dispute process developments, manufacturer positioning, and the evolving rebate landscape. She also unpacks HRSA’s new RFI and what it may indicate for rebate policy direction. Designed for leaders who want clarity—not noise. Visit Virtue 340B’s website to access the full episode and choose your preferred listening or viewing platform.

February’s 340B updates are here—and they’re complicated. In this episode, Katy Lees, Principal 340B Compliance Advisor at Virtue 340B, breaks down paused rebate policies, MFP confusion for hospitals and contract pharmacies, CMS survey decisions, and manufacturer data-sharing challenges. Learn what’s changing, what’s unclear, and how covered entities should prepare next.🎧 Follow the show and send in your questions for future episodes.

Starting January 2026, the Inflation Reduction Act (IRA) will introduce Maximum Fair Prices (MFPs) for select high-cost Medicare Part D drugs—creating a new compliance intersection with the 340B Drug Pricing Program. In Episode 11 of Katy’s 340B Compass, she walks through what these reforms mean for covered entities, including: What the MFP is and how it changes Part D reimbursement Why MFP and 340B discounts cannot apply to the same transaction (duplicate discount risk) HRSA’s proposed 340B Rebate Model Pilot and why it raised major operational and financial concerns How litigation has temporarily paused the rebate pilot, preserving upfront 340B discounts—for now What covered entities must do today to prevent MFP duplicate discounts and confirm MFP rebates are handled correctly for non-340B prescriptions Why vendor limitations may require manual controls and enhanced monitoring in the near term Even with the rebate pilot delayed, the compliance obligation remains; covered entities must actively prevent duplicate discounts and maintain audit-ready documentation. 📥 Download the Slide Deck (Episode Toolkit)https://virtue340b.com/ira-mfp-340b-rebate-pilot-program-guide-toolkit/

In this episode, Katy breaks down what covered entities need to know to prepare for a rebate-based 340B model, including the data elements, workflows, and operational controls that may be required. Important update: after this episode was recorded, a federal court issued a preliminary injunction (Dec. 29, 2025) temporarily blocking HRSA’s 340B Rebate Model Pilot Program from going live on Jan. 1, 2026. While implementation is paused, the readiness concepts discussed remain highly relevant for strengthening data integrity, oversight, and preparedness for future changes.

What should you do when a manufacturer reaches out with a compliance concern? In this episode, Katy explains the fundamentals of good faith inquiries, manufacturer disclosures, and material breach. You’ll learn how to confirm receipt of an inquiry, evaluate potential diversion or duplicate discount issues, determine whether an issue rises to a material breach, and navigate disclosure and repayment with professionalism, transparency, and confidence.